Colchicine did not help knee osteoarthritis in a placebo-controlled trial

Design

Double-blind, placebo-controlled randomised trial, three months

Population

120 patients with symptomatic knee osteoarthritis (Kellgren-Lawrence grade 2 or 3)

Primary outcome

Between-group change in knee pain (visual analogue scale)

Effect

No significant difference in pain, function or effusion; inflammatory biomarkers improved

Pharmacologic options for knee osteoarthritis are limited, and colchicine has been proposed as an anti-inflammatory candidate, with earlier trials giving mixed results. The CLOAK trial tested it rigorously: 120 patients with symptomatic knee osteoarthritis (Kellgren-Lawrence grade 2 or 3) randomised to three months of daily colchicine or placebo, with no concurrent NSAIDs.

There was no benefit on the outcomes that matter to patients. Colchicine did not improve knee pain, KOOS function scores or sonographic effusion size versus placebo, and subgroups with more severe pain, worse radiographic disease or higher hsCRP or urate fared no better. Colchicine did improve several inflammatory serum biomarkers, including hsCRP, which the authors suggest might hint at longer-term benefit.

The practical message is clear for now: do not use colchicine to treat knee osteoarthritis symptoms. The biomarker changes are a reason to study longer-term structural outcomes, not to prescribe it for pain today.

• Double-blind placebo-controlled trial, 120 patients, three months of colchicine for knee osteoarthritis.
• No improvement in knee pain, KOOS function or effusion size versus placebo.
• No benefit even in subgroups with severe pain, worse radiographs, or high hsCRP or urate.
• Colchicine did improve inflammatory biomarkers, including hsCRP.
• Do not use colchicine for osteoarthritis symptoms on current evidence.

Why it matters

It closes off colchicine as a symptomatic treatment for knee osteoarthritis, preventing a futile prescription in a condition short on options.

Don't overread it

A three-month trial of symptoms; the biomarker improvements leave open, but do not demonstrate, a longer-term structural benefit.

The statistics, in plain English

A clean negative on the patient-centred outcomes, with no benefit even in the subgroups most likely to respond, makes the lack of short-term effect reasonably firm; the biomarker changes are secondary and do not establish clinical benefit.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.